Toronto, ON- Oxilight Inc. (SBC Chengdu 2017 Alumni) announced today that it would present its newest technology at the Second Britton Chance International Symposium on Metabolic Imaging/Spectroscopy, which will be on June 11-13, 2018 at the University of Pennsylvania. The event will honor the 105th birthday of Britton Chance.
Gennadi Saiko, Founder and CEO of Oxilight, says “Britton Chance is one of the most distinguished names in biophysics and biochemistry. His students, collaborators, and colleagues have had a profound impact on a variety of fields. We are pleased to participate in the event honoring his legacy.”
Britton Chance’s scientific career spanned eight decades and had been recognized by the US National Medal of Science and memberships in the National Academy of Sciences of six countries. It is rare for a scientist who achieves so much in so many disciplines, as well as excelling at the Olympics (a gold medal in sailing at the 1952 Summer Olympics).
Metabolism was a central theme of Dr. Chance’s research. In the 1930s, he invented miniature stop-flow instruments and used them to make seminal contributions to our understanding of enzymatic kinetics. In the 1950s, he invented the dual-beam spectrophotometer and used it in pioneering investigations of bioenergetics and the redox state in mitochondria. In the 1960s he discovered electronic tunneling processes in biological systems. In the 1970s he identified hydrogen peroxide released by the respiratory chain in mitochondria. In the 1970-80s, he was a key player in the development of in vivo NMR spectroscopy, and in the 1990s he was a founding father of the field of biophotonics, especially for biomedical research and clinical practice.
The symposium aims to showcase cutting-edge research innovation and clinical translation in metabolic imaging and spectroscopy by methods such as optics, NMR, nuclear medicine, mass spectrometry, ultrasound. It will bring together physicists, engineers, biologists, and clinicians for discussion and presentation of recent innovations and clinical progress.
About Oxilight: Oxilight Inc is a Toronto-based medical device company with a vision to revolutionize wound care by enabling frontline health professionals to assess wound status anytime and anywhere. Oxilight brings to the market an innovative wound imaging system, which provides physicians with physiologically relevant information about chronic wounds. Oxilight uses multispectral imaging technology to retrieve information about perfusion and oxygenation in wound bed and peri-wound.
For further information please contact Oxilight Inc at firstname.lastname@example.org. Follow Oxilight on Twitter (@Oxilight_Canada).